SYK stock forecast, quote, news & analysis

Key Takeaways

• Stryker shares have rebounded approximately 8.8% over the past 30 days, recovering from the 52-week low of $281.00 reached in mid-May 2026.
• First-quarter 2026 results missed Wall Street estimates, with revenue of $6.02 billion and adjusted EPS of $2.60, partly reflecting disruption from a cyber incident earlier in the year.
• Wall Street maintains a broadly bullish consensus, with 17 Buy ratings and 4 Hold ratings, and an average 12-month price target near $388.
• The company completed its acquisition of Amplitude Vascular Systems for up to $835 million, expanding its peripheral vascular portfolio with next-generation intravascular lithotripsy technology.
• Multiple new product launches — including the TPX HD power tool and the Pangea Plating System in Europe — underscore Stryker's continued investment in innovation.

Current Market Snapshot

Stryker Corporation (SYK) closed at $332.71 on June 26, 2026, reflecting a notable recovery from the 52-week low of $281.00 set on May 11. The stock remains well below its 52-week high of $404.87 reached in July 2025, and is down roughly 17.5% on a year-over-year basis. With a market capitalization of approximately $123 billion and a trailing P/E ratio near 37, Stryker continues to trade at a premium relative to the broader medical device sector, reflecting investor confidence in its long-term growth trajectory despite near-term headwinds. The healthcare sector has experienced mixed sentiment in 2026, with medical device stocks facing pressure from macroeconomic uncertainty, yet Stryker's diversified portfolio and consistent innovation pipeline have helped stabilize the stock in recent weeks.

Stryker Corporation (SYK) Business Overview and Competitive Position

Stryker Corporation, headquartered in Portage, Michigan, is one of the world's largest medical technology companies, operating through two primary segments: MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment encompasses surgical equipment, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, and neurovascular products. The Orthopaedics segment includes implants for hip, knee, and shoulder joint replacements, as well as trauma and extremities surgeries. Stryker's Mako robotic-arm assisted surgery platform remains a key competitive differentiator, driving procedure volumes and reinforcing the company's leadership in surgical robotics. With products sold in over 75 countries and approximately 56,000 employees, Stryker generated $25.12 billion in revenue in fiscal 2025. The company's scale, diversified product lines, and consistent investment in research and development — approximately $1.6 billion annually — position it as a dominant force in the global medical device industry alongside peers such as Intuitive Surgical, Boston Scientific, and Zimmer Biomet.

Recent Developments Driving SYK

Several developments have shaped Stryker's stock performance over the past 30 days. The most significant catalyst was the continued recovery from the cyber incident disclosed earlier in 2026, which disrupted operations and weighed on first-quarter results. Q1 2026 revenue of $6.02 billion missed consensus estimates of $6.33 billion, while adjusted EPS of $2.60 came in below the $2.98 consensus. Despite the miss, management reaffirmed full-year 2026 guidance, signaling confidence in a second-half recovery. On the product front, Stryker launched the TPX HD premium small bone power tool in early June and announced the European launch of its Pangea Plating System for fracture treatment. The company also completed the acquisition of Amplitude Vascular Systems (AVS) in May, adding a next-generation intravascular lithotripsy platform to its peripheral vascular portfolio for up to $835 million. In late June, Stryker announced a partnership with professional golfer Shane Lowry to spotlight the caregiver journey in joint replacement. On the analyst front, while most firms maintained Buy ratings following the Q1 report, numerous price targets were trimmed — Bank of America lowered its target from $450 to $380, Barclays from $469 to $394, and Deutsche Bank from $402 to $315 — reflecting tempered near-term expectations. The stock's subsequent rebound from its May lows suggests the market has largely absorbed the Q1 reset and is looking toward operational recovery.

Trending AI Robots

For investors seeking data-driven approaches to navigate evolving market conditions, Tickeron's Trending AI Robots page offers a curated view of top-performing AI-powered trading bots. Tickeron hosts hundreds of AI trading bots that actively trade thousands of tickers across diverse strategies, timeframes, and performance metrics. Only the most relevant and consistently high-performing bots are featured in this curated section, allowing users to quickly identify strategies that align with their trading objectives. Whether focused on short-term momentum, swing trading, or longer-term trend following, the platform provides transparency into bot performance, helping traders make more informed decisions. Exploring the Trending AI Robots page can serve as a valuable starting point for those looking to integrate algorithmic insights into their investment process.

2026 Outlook and What Investors Should Watch

Looking ahead, Stryker's second-quarter earnings report — expected around late July 2026 — will be a critical checkpoint for investors assessing the pace of operational recovery following the cyber incident. Key metrics to monitor include organic revenue growth, procedure volume trends across the Mako robotics installed base, and margin progression. The integration of the AVS acquisition and its contribution to the peripheral vascular business will also be closely watched. Macroeconomic factors, including interest rate policy and hospital capital spending trends, remain relevant given Stryker's exposure to capital equipment sales. Additionally, any further developments related to the cybersecurity investigation — law firm Berger Montague announced a probe into the board's oversight of data protection practices in April — could influence sentiment. On the innovation front, continued adoption of the Mako platform and new product ramps such as the Pangea Plating System and TPX HD will be important growth drivers. With analyst consensus remaining firmly in Buy territory and an average price target implying roughly 17% upside from late-June levels, the market appears positioned for a gradual recovery, though execution in the coming quarters will be essential to sustaining the recent momentum.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations